Altamira Advances Circular RNA Delivery Technology

Altamira Therapeutics Ltd is a company dedicated to the development of RNA delivery technologies for targets beyond the liver. The company has reported positive results on its nanoparticle-based platform for circular mRNA deliverance. In vitro cell and tissue studies proved the cell transfection efficiency and the essential enhancement of protein expression compared with the linear mRNA. Accordingly, Altamira has recorded a provisional application with the United States Patent and Trademark Office (USPTO).

Company to launch new circular RNA applications under the CycloPhore™ brand, which complements its customizable RNA delivery services OligoPhore™ for siRNA and SemaPhore™ for mRNA. This development is expected to expand the opportunities in Altamira to partner with more companies in the biotech and pharmaceutical industries.

Covadonga Pañeda, PhD, Altamira Therapeutics’ Chief Operating Officer, said in a statement, “We are very excited about the potential for CycloPhore as circular mRNA has been attracting great interest in drug development thanks to enhanced protein expression and greater stability compared to linear mRNA. For instance, circular mRNA could allow for lower dosing and less frequent administrations than linear mRNA, which may be very important for certain therapeutic indications or vaccines.”

She also commented, “CycloPhore provides further testimony to the versatility of our delivery platform across different RNA modalities. We expect that the expansion of our platform into this exciting new RNA modality, together with the platform’s ability to deliver extrahepatically and promote strong endosomal escape, will make CycloPhore an attractive tool for drug developers looking for delivery vehicles that fit their specific needs.”